Joenväärä, S., Holm, M., Saraswat, M. et al. Quantitative urine proteomics in pregnant women for the identification of predictive biomarkers for preeclampsia. transl med commun 7, 1 (2022). https://doi.org/10.1186/s41231-022-00108-6
Quantitative urine proteomics in pregnant women for the identification of predictive biomarkers for preeclampsia
|Author:||Joenväärä, Sakari1; Holm, Matilda1; Saraswat, Mayank1;|
1Transplantation laboratory, Faculty of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
2Department of Reproductive Biology, All India Institute of Medical Sciences, New Delhi, India
3Finnish Institute for Health and Welfare, Helsinki, Finland
4Children’s Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
5PEDEGO Research Unit, MRC Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland
6Department of Psychology and Logopedics, Faculty of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
7Department of Obstetrics and Gynecology, Tampere University Hospital, Tampere, Finland
8Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
9Department of Medical and Clinical Genetics, Faculty of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
10Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland
11Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
12Hyvinkää Hospital, Helsinki and Uusimaa Hospital District, Hyvinkää, Finland
13Department of Clinical Chemistry, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
14Department of Clinical Chemistry, Institute of Clinical Medicine, University of Eastern Finland, Kuopio University Hospital, Kuopio, Finland
|Online Access:||PDF Full Text (PDF, 1.5 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe20231006138976
|Publish Date:|| 2023-10-06
Background: Preeclampsia (PE) is a life-threatening disease characterized by elevated blood pressure and proteinuria. Predictive biomarkers of PE are needed, especially those predicting PE in early pregnancy. The aim of this pilot study was to identify urine proteins that could be candidates for new non-invasive markers for PE.
Methods: Urine samples at three time points of pregnancy (12–14, 18–20 and 26–28 weeks of gestation) were prospectively collected from high-risk women who subsequently developed PE (n = 7), high-risk women who did not develop PE (n = 6), and women without known risk factors for PE (n = 4). The samples were analyzed using mass spectrometry and we subsequently quantified 361 proteins used for further analysis. Rigorous statistical analysis with multiple methods was performed to identify biomarker candidates.
Results: Of the clinical risk factors analyzed, pre-pregnancy body mass index (BMIBP) was found to be the most important predictor of PE. We identified multiple proteins that correlated with BMIBP and could improve the prediction of PE in combination with BMIBP. Other statistical analyses identified six proteins that each could differentiate women who subsequently developed PE from those who did not at all three time points.
Conclusions: We identified multiple urine proteins that could be used to predict PE in combination with BMIBP. We also identified six proteins that are strong candidates for predicting PE already in early pregnancy.
Translational medicine communications
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
3121 General medicine, internal medicine and other clinical medicine
3123 Gynaecology and paediatrics
This work was supported by the University of Helsinki (HL, PV), Finska Läkäresällskapet (HL), EVO research funding (a special Finnish state subsidy for health science research [HL, EH]), the Academy of Finland (EK, KR, HL), the Signe and Ane Gyllenberg Foundation (EK, KR), the Sigrid Juselius Foundation (EK), the Finnish Medical Foundation (HL), the Foundation for Pediatric Research (Lastentautien tutkimussäätiö, EK), the Novo Nordisk Foundation (EK), the Jane and Aatos Erkko Foundation (HL), and the Päivikki and Sakari Sohlberg Foundation (HL, PV). The funders had no role in the design of the study, data collection and analysis, interpretation of the data, or writing the manuscript.
© The Author(s) 2022. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.